Quantikine Immunoassay Control 1105 for h/cm PD-L1/B7-H1

• Reactivity: Hu, Pm-Cm
• Applications: Ctrl
• Conjugate: Unconjugated

Quantikine Immunoassay Control 1105 for h/cm PD-L1/B7-H1 Summary

• Additional Information: For use with catalog number DB7H10
• Source: N/A
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details

Applications/Dilutions

• Dilutions:
  • Control

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Quantikine Immunoassay Control 1105 for h/cm PD-L1/B7-H1

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

PD-L1, also known as B7-H1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, enothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma. PD-L1 binds to T cell B7-1/CD80 and PD-1. It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells. It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development. PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells. In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells.

Publications for PD-L1 (QC226)(2)

Publications using QC226

• Király, Z;Nagy, E;Bokor, L;Kovács, A;Marschalkó, M;Hidvégi, B; The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus-A Pilot Study Journal of clinical medicine 2023-08-30 [PMID: 37685714] (Human)
• A Vikerfors, S Davidsson, J Frey, T Jerlström, J Carlsson Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients Cancer, 2021-11-21;13(22):. 2021-11-21 [PMID: 34830993] (Human)